Advanced Therapy for Hepatitis C

"Advanced Therapy for Hepatitis C: McCaughan/Advanced Therapy for Hepatitis C" by McCaughan, Geoffrey W. (editor);McHutchison, John G. (editor);Pawlotsky, Jean-Michel (editor), published by Wiley-Blackwell. According to the WHO, 170 million people, or 3% of the world's population, are infected with Hepatitis C and at risk of developing liver cirrhosis and/or liver cancer. 3-4 million people each year are newly diagnosed carriers of the virus. Advanced Therapy for Hepatitis C Infection provides you with expert guidance from the world’s leading hepatologists on the very latest treatment options for patients with the HCV virus. Focusing mainly on the efficacy and clinical use of antiviral therapies, key topics include: Treatment of recurrent hepatitis C following liver transplantation Content: Chapter 1 HCV Replication (pages 1–11): Michael R. Beard Chapter 2 Hepatitis C Virus Genotypes (pages 12–16): Scott A. Read and Mark W. Douglas Chapter 3 Immune Responses to HCV: Implications for Therapy (pages 17–24): David G. Bowen Chapter 4 Mechanisms of Action of Antiviral Drugs: The Interferons (pages 25–35): Edmund Tse and Michael R. Beard Chapter 5 Pharmacology and Mechanisms of Action of Antiviral Drugs: Ribavirin Analogs (pages 36–42): Fred Poordad and Grace M. Chee Chapter 6 Pharmacology and Mechanisms of Action of Antiviral Drugs: Polymerase Inhibitors (pages 43–52): Lotte Coelmont, Leen Delang, Mathy Froeyen, Piet Herdewijn and Johan Neyts Chapter 7 Pharmacology and Mechanisms of Action of Antiviral Drugs: Protease Inhibitors (pages 53–59): Laurent Chatel?Chaix, Martin Baril and Daniel Lamarre Chapter 8 Measuring Antiviral Responses (pages 60–63): Jean?Michel Pawlotsky and Stephane Chevaliez Chapter 9 Genotype 1: Standard Treatment (pages 65–73): Rebekah G. Gross and Ira M. Jacobson Chapter 10 Individually Tailored Treatment Strategies in Treatment?naive Chronic Hepatitis C Genotype 1 Patients (pages 74–83): Johannes Wiegand and Thomas Berg Chapter 11 Genotype 1 Relapsers and Non?Responders (pages 84–89): Salvatore Petta and Antonio Craxi Chapter 12 Standard Therapy for Genotypes 2/3 (pages 90–96): Kenneth Yan and Amany Zekry Chapter 13 Altered Dosage or Durations of Current Antiviral Therapy for HCV Genotypes 2 and 3 (pages 97–103): Alessandra Mangia, Leonardo Mottola and Angelo Andriulli Chapter 14 Genotypes 2 and 3 Relapse and Non?Response (pages 104–112): Stella Martinez, Jose Maria Sanchez?Tapias and Xavier Forns Chapter 15 Hepatitis C Genotype 4 Therapy: Progress and Challenges (pages 113–126): Sanaa M. Kamal Chapter 16 Antivirals in Acute Hepatitis C (pages 127–131): Heiner Wedemeyer Chapter 17 Antivirals in Cirrhosis and Portal Hypertension (pages 132–139): Diarmuid S. Manning and Nezam H. Afdhal Chapter 18 Treatment of Recurrent Hepatitis C Following Liver Transplantation (pages 140–149): Ed Gane Chapter 19 Antiviral Treatment in Chronic Hepatitis C Virus Infection with Extrahepatic Manifestations (pages 150–159): Benjamin Terrier and Patrice Cacoub Chapter 20 Cytopenias: How they Limit Therapy and Potential Correction (pages 160–168): Mitchell L. Shiffman Chapter 21 The Problem of Insulin Resistance and its Effect on Therapy (pages 169–176): Venessa Pattullo and Jacob George Chapter 22 HIV and Hepatitis C Co?Infection (pages 177–184): Gail V. Matthews and Gregory J. Dore Chapter 23 HCV and Racial Differences (pages 185–189): Andrew J. Muir Chapter 24 HCV and the Pediatric Population (pages 190–195): Kathleen B. Schwarz Chapter 25 New Horizons: IL28, Direct?Acting Antiviral Therapy for HCV (pages 196–213): Alexander J. Thompson, John G. McHutchison and Geoffrey W. McCaughan Book details: 225 pages, published 2011. Order now on BookShops.in with fast, reliable delivery across India.